Magnetically active Fe3O4 nanorods loaded with tissue plasminogen activator for enhanced thrombolysis

Systemic thrombolysis with intravenous tissue plasminogen activator (tPA) remains the only proven treatment that is effective in improving the clinical outcome of patients with acute ischemic stroke. However, thrombolytic therapy has some major limitations such as hemorrhage, neurotoxicity, and the short time window for the treatment. In this study, we designed iron oxide (Fe3O4) nanorods loaded with 6% tPA, which could be released within ~30 min. The Fe3O4 nanorods could be targeted to blood clots under magnetic guidance. In addition, the release of tPA could be significantly increased using an external rotating magnetic field, which subsequently resulted in a great improvement in the thrombolytic efficiency. Systematic and quantitative studies revealed the fundamental physical processes involved in the enhanced thrombolysis, while the in vitro thrombolysis assay showed that the proposed strategy could improve thrombolysis and recanalization rates and reduce the risk of tPA-mediated hemorrhage in vivo. Such a strategy will be very useful for the treatment of ischemic stroke and other deadly thrombotic diseases such as myocardial infarction and pulmonary embolism in clinical settings.

[1]  T. Olsen,et al.  Stroke. Neurologic and functional recovery the Copenhagen Stroke Study. , 1999, Physical medicine and rehabilitation clinics of North America.

[2]  Yunhua Gao,et al.  In vivo thrombolysis with targeted microbubbles loading tissue plasminogen activator in a rabbit femoral artery thrombus model , 2014, Journal of Thrombosis and Thrombolysis.

[3]  D. Ingber,et al.  Shear-Activated Nanotherapeutics for Drug Targeting to Obstructed Blood Vessels , 2012, Science.

[4]  C. Robic,et al.  Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. , 2008, Chemical reviews.

[5]  B. Furie,et al.  Mechanisms of thrombus formation. , 2008, The New England journal of medicine.

[6]  T Brott,et al.  Treatment of acute ischemic stroke. , 2000, The New England journal of medicine.

[7]  G. Moneta,et al.  Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke , 2009 .

[8]  G. Albers,et al.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.

[9]  Toh-Ming Lu,et al.  Novel Nano-Column and Nano-Flower Arrays by Glancing Angle Deposition , 2002 .

[10]  S. Diamond,et al.  Engineering design of optimal strategies for blood clot dissolution. , 1999, Annual review of biomedical engineering.

[11]  S. Smye,et al.  A mathematical model of post-canalization thrombolysis. , 2002, Physics in medicine and biology.

[12]  Feng Yan,et al.  Microbubbles and ultrasound-mediated thrombolysis: a review of recent in vitro studies , 2012 .

[13]  Adnan I. Qureshi,et al.  Guidelines for the Early Management of Adults With Ischemic Stroke , 2007 .

[14]  Leidong Mao,et al.  Acceleration of Tissue Plasminogen Activator-Mediated Thrombolysis by Magnetically Powered Nanomotors , 2014, ACS nano.

[15]  P. Armstrong,et al.  Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 2. , 2001, Circulation.

[16]  P. Decuzzi,et al.  TPA Immobilization on Iron Oxide Nanocubes and Localized Magnetic Hyperthermia Accelerate Blood Clot Lysis , 2015 .

[17]  Jyh-Ping Chen,et al.  Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle , 2012, International journal of nanomedicine.

[18]  W. Chandler,et al.  Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. , 1997, Circulation.

[19]  A. Rosengart,et al.  Physicochemical characteristics of magnetic microspheres containing tissue plasminogen activator , 2007 .

[20]  Jyh-Ping Chen,et al.  Characterization of chitosan magnetic nanoparticles for in situ delivery of tissue plasminogen activator , 2011 .

[21]  H. Cameron,et al.  Regulation of adult neurogenesis by excitatory input and NMDA receptor activation in the dentate gyrus , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[22]  Ralph Weissleder,et al.  Multifunctional magnetic nanoparticles for targeted imaging and therapy. , 2008, Advanced drug delivery reviews.

[23]  Takashi Inoue,et al.  Randomized Trial of Intraarterial Infusion of Urokinase Within 6 Hours of Middle Cerebral Artery Stroke: The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan , 2007, Stroke.

[24]  S L Diamond,et al.  Inner clot diffusion and permeation during fibrinolysis. , 1993, Biophysical journal.

[25]  U. Schwertmann,et al.  The Iron Oxides: Structure, Properties, Reactions, Occurrences and Uses , 2003 .